Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Chimeric antigen receptor (CAR) T cell therapy has transformed hematologic cancer treatment.
• Significant challenges hinder CAR T cell efficacy in solid tumors, including antigen heterogeneity and immunosuppressive tumor microenvironments.
• Overcoming these obstacles is crucial for expanding CAR T cell therapy applications.

Purpose of the Study:

• To provide a comprehensive review of recent advances in CAR T cell therapy for solid tumors.
• To discuss strategies for identifying and targeting tumor-specific antigens.
• To highlight innovations in CAR T cell engineering, manufacturing, and overcoming therapeutic limitations.

Main Methods:

• Review of recent preclinical and clinical studies on CAR T cell therapy for solid tumors.
• Analysis of novel CAR T cell engineering strategies, including structural innovations and chemokine receptor incorporation.
• Discussion of advanced manufacturing techniques and methods to mitigate adverse effects and improve persistence.

Main Results:

• Advances in antigen identification and CAR T cell targeting are improving specificity for solid tumors.
• Engineered CAR T cells with enhanced infiltration and activity in immunosuppressive microenvironments show promise.
• Novel manufacturing approaches and strategies to manage side effects like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are emerging.

Conclusions:

• CAR T cell therapy holds significant potential for treating solid tumors through innovative engineering and manufacturing.
• Addressing challenges like antigen heterogeneity and the tumor microenvironment is key to clinical success.
• Future directions involve combination therapies and genetic modifications to enhance CAR T cell functionality and durability.